4D Pharma PLC (DDDD) 2021年年度报告「LSE」.pdf

1、4D pharma plcAnnual Report and Accounts 2021ContentsHighlights 1Directors,Secretary and Advisors 3Strategic report:Introduction 4Strategic report:Business strategy 5Strategic report:Chairperson and CEOs statement 7Strategic report:Business overview 12 Strategic report:Financial review 16 Strategic r

2、eport:Principal risks and uncertainties 23 Corporate governance:Corporate governance report 28Corporate governance:Report of the Audit and Risk Committee 32Corporate governance:Directors remuneration report:Letter 34Corporate governance:Directors remuneration report:Policy 36Corporate governance:Dir

3、ectors remuneration report:Report 45Corporate governance:Directors report 51Corporate governance:Statement of Directors responsibilities 55Independent auditors report to the members of 4D pharma plc 56Group statement of total comprehensive income 62Group statement of financial position 63Company sta

4、tement of financial position 64Group statement of changes in equity 65Company statement of changes in equity 66Group cash flow statement 67Company cash flow statement 68Notes to the financial statements 694D pharma plc Annual Report and Accounts 2021 1 Highlights Financial highlights Loss for the ye

5、ar and total comprehensive loss for the year(54.7m)Expenditure on research and development(19.8m)Total equity(23.2m)Cash,cash equivalents and cash on deposit(15.5m)Loss per share(31.83 pence)020406020192020202101020302019202020210204020192020202101020201920202021010203040502019202020214D pharma plc

6、Annual Report and Accounts 2021 2 Highlights(continued)Operational highlights Provided an update on the ongoing clinical trial portfolio for lead oncology candidate MRx0518.This included the first announcement of signals of anti-tumor activity for the combination of MRx0518 with Keytruda in bladder